NEW YORK (GenomeWeb) – Rosetta Genomics today said that it plans to redirect “substantially all of our sales and marketing resources” to promote is RosettaGx Reveal test, following a preliminary 54 percent quarter over quarter growth in sales of the microRNA-based assay for classifying indeterminate thyroid nodules.
Get the full story This story is free
for registered users
Registering provides access to this and other free content.
Already have an account?